Public Accounts CommitteeWritten evidence from National Institute for Health and Care Excellence

At the end of the meeting of the Committee for Public Accounts on Monday 17 June, during which the Committee considered access, by NICE, to data from pharmaceutical companies, you asked me to write to you with the revised wording of the declaration we ask company medical directors to sign.

The current wording is:

“I confirm that all relevant data pertinent to the [STA] [MTA] have been disclosed to the Institute.
(Signed) Medical Director (or equivalent)”.

Note: STA and MTA refer to the two different forms of appraisal we use.

From August, we intend to use the following wording:

“I confirm that all the data necessary to address the remit and scope of the technology appraisal as issued by the Department of Health and NICE, within the Company’s or any of its associated companies’ possession, custody, or control in the UK or elsewhere in the world, have been disclosed to NICE or its authorised agents.
(Signed) Medical Director (or equivalent senior registered medical practitioner”.

Sir Andrew Dillon
Chief Executive

26 June 2013

Prepared 30th December 2013